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AbstrAct
Background Proton pump inhibitor (PPI) use is 
widespread. There have been increasing concerns about 
overuse of high- dose PPIs for durations longer than 
clinically necessary.
Objective To evaluate the impact of national education 
initiatives on reducing PPI use in Australia.
Design Population- based, controlled interrupted 
time series analysis of PPI dispensing claims data for 
Australian adults from July 2012 to June 2018; we used 
statin dispensing as a control.
Interventions A year- long educational initiative led by 
NPS MedicineWise (previously the National Prescribing 
Service) from April 2015. Simultaneously, Choosing 
Wisely released recommendations in April 2015 and May 
2016. Both promoted review of prolonged PPI use and 
encouraged stepping down or ceasing treatment, where 
appropriate.
Measurements We examined monthly changes in 
PPI (and statin) dispensing (stratified by high, standard 
and low tablet strength), rates of switching from higher 
to lower strength PPIs and rates of PPI (and statin) 
discontinuation.
Results We observed 12 040 021 PPI dispensings to 
579 594 people. We observed a sustained −1.7% (95% 
CI: −2.7 to −0.7%) decline in monthly dispensing of 
standard strength PPIs following the initiatives until 
the end of the study period. There were no significant 
changes in high or low strength PPI (or statin) 
dispensings, switching to lower strength PPIs, or PPI (and 
statin) treatment discontinuation.
Conclusion Our findings suggest that these educational 
initiatives alone were insufficient in curbing overuse of 
PPIs on a national level. Concerted efforts with policy 
levers such as imposing tighter restrictions on subsidised 
use of PPIs may be more effective. Noting low strength 
esomeprazole is not publicly subsidised in Australia, 
availability of these preparations may also facilitate more 
appropriate practice
IntroductIon
In the past two decades, proton pump 
inhibitors (PPIs) have become the 
ubiquitous treatment for managing 
gastrointestinal- acid- related disor-
ders globally.1–7 These disorders are 
widespread in Western societies with 
worldwide prevalence estimates for 
gastro- oesophageal reflux disease 
(GORD) ranging from 10% to 20%8 and 
5% to 10% for peptic ulcer disease.9 PPIs 
are also commonly prescribed prophylac-
tically to prevent stress ulcers and upper 
gastrointestinal bleeding, which may be 
induced by treatment with non- steroidal 
anti- inflammatory drugs or certain anti-
coagulant medicines.7 10 Contemporary 
prevalence estimates of PPI use range 
internationally from 7% to 16%2 4 5; it is 
estimated that 15% of Australian adults 
were dispensed at least one PPI in 2017.11
PPIs have an excellent safety profile 
when used for short periods; however, 
concerns are growing regarding their 
long- term use due to increased risks of 
bone fractures, vitamin B12 and magne-
sium deficiencies, and Clostridium difficile 
infection, especially in older people.12–14 
Furthermore, recent evidence suggests 
an increased risk of mortality with 
prolonged PPI use, specifically mortality 
due to cardiovascular disease, chronic 
kidney disease and upper gastrointestinal 
cancer.15 The rapid rise in PPI use since 
their introduction to the market in the 
1990s16 has prompted widespread trep-
idation about their overuse, particularly 
the use of higher dose PPIs for durations 
longer than clinically necessary.2 4 17 18
Contemporary clinical treatment 
guidelines for common gastro- intestinal- 
acid- related disorders recommend initial 
treatment with standard strength PPIs 
for 4–8 weeks.19–21 After initial treat-
ment, if symptoms persist, guidelines 
recommend a step- down approach where 
patients continue PPIs on a lower dose 
and attempt to discontinue treatment. 
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Table 1 Classifications and date each PPI medicine was made available as an over- the- counter medicine
PPI medicine ATC code High strength Standard strength Low strength
Date medicine became available 
over the counter
Omeprazole A02BC01 – 20 mg* 10 mg June 2016
Pantoprazole A02BC02 – 40 mg 20 mg* June 2015
Lansoprazole A02BC03 – 30 mg 15 mg* June 2016
Rabeprazole A02BC04 – 20 mg 10 mg* June 2016
Esomeprazole A02BC05 40 mg 20 mg* – February 2016
*The strength of PPI medicine rescheduled to over- the- counter medicine (Therapeutic Goods Administration et al.)57
ATC, Anatomical Therapeutic Chemical; PPI, proton pump inhibitor.
However, evidence suggests that real- world PPI 
use is discordant with these evidence- based guide-
lines.18 22 Reasons cited for this evidenced- practice 
discrepancy include patient preference for treatment, 
fears of rebound hypersecretion on discontinuation, 
practitioner time constraints and poor communica-
tion, particularly between primary care and in hospital 
prescribers.18 23–27
In an attempt to curb escalating and potentially inap-
propriate PPI use in Australia, two national initiatives 
were launched in 2015. NPS MedicineWise, an agency 
(previously the National Prescribing Service) estab-
lished to improve the quality use of medicines as part 
of Australia’s National Medicines Policy,28 introduced 
a year- long, multifaceted educational programme 
focused on changing prescribers’ behaviour to align 
with guideline recommended care for PPIs. At the same 
time, Choosing Wisely Australia (hereafter referred 
to as Choosing Wisely) as part of a grassroots, physi-
cian- led international initiative aiming to identify and 
reduce low- value practices (also facilitated in Australia 
by NPS MedicineWise)29 published two recommenda-
tions relating to appropriate PPI prescribing.
In this study, we evaluated the impact of the NPS 
MedicineWise educational initiative and the Choosing 
Wisely recommendations on PPI use in Australia. 
Specifically, we estimated changes in PPI utilisation, 
following these initiatives, including dispensings, 
switching from higher to lower strength PPIs and 
discontinuation of PPI treatment among Australian 
adults.
Methods
study setting and population
In Australia, all citizens and residents are entitled to 
subsidised prescription medicines via the Pharmaceu-
tical Benefits Scheme (PBS). We used dispensing records 
from 1 July 2012 to 31 June 2018 for a random 10% 
sample of all PBS- eligible Australian residents. The 
PBS 10% sample is a standardised dataset provided 
by the Australian Government Department of Human 
Services for analytical use which captures PBS medi-
cine dispensings.30 These de- identified, individual- 
level data include complete demographic information 
(gender and year of birth) and PBS dispensing records 
(date of dispensing, dispensed medicine, dispensed 
medicine strength, quantity dispensed, prescriber 
specialty). Private prescriptions (ie, not PBS subsi-
dised) and over- the- counter medicine dispensings are 
not captured in the data.
We restricted our study to individuals aged ≥18 years 
with at least one dispensing of a PBS- listed medicine.
Medicines of interest
We included all strength and formulations of PBS- listed 
PPI medicines corresponding to the WHO Anatom-
ical Therapeutic Chemical (ATC) classification code 
A02BC.31 These were as follows: omeprazole, panto-
prazole, lansoprazole, rabeprazole and esomeprazole. 
We classified PPI tablet strengths as high, standard 
and low according to the guidelines by Australian 
Therapeutic Guidelines and the National Institute 
for Health and Care Excellence guideline (CG184; 
table 1).19 20 We excluded PPIs in combination with 
antibiotics (ATC code: A02BD) prescribed for the 
acute treatment of Helicobacter pylori infection.
We used statins as a control medicine in our evalua-
tion to strengthen assumptions that any changes in PPI 
use were related to the interventions rather than extra-
neous factors concurrently affecting the dispensings of 
other medicines. We chose statins as they are used by 
similar populations to those using PPIs and the initia-
tives under study were unlikely to affect their use.32 
We included the following PBS- listed statin medicines 
(ATC code C10AA): simvastatin, pravastatin, fluvas-
tatin, atorvastatin and rosuvastatin.
Initiatives evaluated
In April 2015, NPS MedicineWise implemented a 
12- month educational programme primarily targeting 
general practitioners (GPs) with the aim of changing 
PPI prescribing behaviour to better reflect best- 
practice guidelines. First, the programme targeted all 
GPs across Australia by mailing information and feed-
back about their own PPI prescribing compared with 
other GPs, based on nationwide claims data.
Second, this initiative delivered key messages on 
PPI prescribing to GPs, other health professionals 
(eg, pharmacists and nurses) and consumers through 
a number of active and passive interventions. A 
variety of resources and activities were made avail-
able through a centralised online portal accessed via 
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the NPS MedicineWise website. Active interventions 
included a clinical e- audit, where GPs could upload 
10 of their patients’ clinical information and receive 
immediate and dynamic patient- specific recommenda-
tions and a national case study, available to all health 
professionals, in which interactive clinical scenarios 
were presented with feedback and expert commen-
tary related to PPI therapy. Completion of these 
activities was incentivised through professional devel-
opment points, recognised by health professionals in 
Australia.33
Passive interventions included educational resources 
for health professionals on PPIs and the management 
of GORD, including an expert- led two- part video 
called PPIs: Too Much of a Good Thing, up- to- date 
evidenced- practice summary sheets, factsheets to 
display in a workplace and a downloadable symp-
tomatic management pad to help create personalised 
PPI therapy plans with patients. In parallel, NPS 
MedicineWise and Choosing Wisely also developed 
online resources such as leaflets, factsheets and articles 
targeting consumers. These provided practical infor-
mation for patients about the management of GORD 
and also promoted conversation between patients and 
practitioners.34 35
The following recommendations were released, in 
April 2015 and May 2016, as a part of the Choosing 
Wisely campaign and underpinned the key messages of 
the initiatives promoting appropriate PPI prescribing.
 ► Do not use proton pump inhibitors (PPIs) long- term in 
patients with uncomplicated disease without regular 
attempts at reducing dose or ceasing.36
 ► Do not continue prescribing long- term proton pump 
inhibitor (PPI) medication to patients without attempting 
to reduce the medication down to the lowest effective 
dose or cease the therapy altogether.37
By providing patient- specific feedback to prescribers 
and education to both health professionals and 
consumers, the components of each intervention 
aimed to facilitate consumer and prescriber interac-
tions to enable best- practice prescribing. These inher-
ently address some of the root causes of inappropriate 
PPI prescribing, for example, patient preference for 
treatment and/or fear of discontinuation.
Measures and statistical analysis
In this population- based, retrospective observational 
study, we examined three measures of PPI utilisation 
dispensings counts, discontinuation of treatment and 
switches to lower strength PPIs.
We defined discontinuation of treatment as the 
absence of PPI (or statin) dispensings within 90 days of 
the last dispensing. The discontinuation date was esti-
mated by adding the expected duration of a dispensing 
to the last dispensing (ie, 30 days—median duration 
between dispensings).
We recorded switches to lower strength PPIs when 
a subsequent dispensing for a person was of a lower 
strength PPI (ie, dispensing of high strength PPI 
followed by a standard or low strength PPI dispensing). 
To capture people who had reinitiated treatment on a 
lower strength, we did not apply restrictions in time 
between dispensings.
The main study measures did not capture the step-
ping down of PPI treatment if people remained on 
the same tablet strength but reverted to less frequent 
intake for example, one tablet every other day. To 
explore whether this practice became more common 
after the initiatives, we conducted a supplementary 
analysis plotting the days between dispensings in the 
year before, during and after the NPS MedicineWise 
PPI programme and Choosing Wisely recommen-
dations. We would expect to observe an increase in 
the time between dispensings after the initiatives had 
treatment been stepped down by less frequent intake.
In our analysis, we first described the above 
measures in the year before (April 2014–April 2015) 
and the year after (May 2016–May 2017) the NPS 
MedicineWise PPI programme and Choosing Wisely 
recommendations. We stratified each by strength 
and medicine. For discontinuation, this was stratified 
by the medicine first dispensed within the observed 
course of treatment. For switching, we stratified by 
medicine switched from.
Second, to assess the impact of the initiatives we 
calculated the following rates:
1. Monthly dispensing counts for PPIs (stratified by tablet 
strength) and statins (July 2012–June 2018).
2. Monthly rates of treatment discontinuation (PPIs and 
statins): calculated by dividing the number of discontinu-
ations by the number of people treated within the month 
(we restricted the time period to January 2013 to May 
2018 to ensure that we had enough time to ascertain 
treatment and discontinuation).
3. Monthly rates of switches to lower strength PPIs: cal-
culated by dividing the number of switches to a lower 
strength PPI divided by the number of people dispensed 
high or standard strength PPIs within the month (we re-
stricted the time period to January 2013–May 2018 to 
ensure that we had enough time to ascertain treatment 
and switching).
We used controlled interrupted times series analyses 
with seasonal autoregressive integrated moving average 
modelling for each of the above rates, so as to account 
for non- stationarity, seasonality and autocorrelation in 
the data. PBS dispensing data are commonly subject to 
seasonality; due to the effect of the PBS Safety Net.30 
This can lead to stockpiling in the latter months of the 
year, resulting in increased rates of dispensing towards 
the end of the year and a subsequent fall early in the 
following year. We applied Box- Jenkins methodology 
to determine the best fitting models for each anal-
ysis.38 We used two intervention points: one in April 
2015 marking the beginning of the NPS MedicineWise 
PPI programme and the release of the first Choosing 
Wisely PPI recommendation; and one for May 2016 
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Figure 1 (A) Monthly unadjusted and seasonally adjusted (dashed 
line) dispensing counts of PPIs and statins; (B) dispensing counts of PPIs 
by strength: high, standard and low, from July 2012 to June 2018. NPS 
MedicineWise’s PPI program start and end and Choosing Wisely Australia 
recommendations 1 and 2 marked at April 2015 and may 2016. Standard 
strength PPI esomeprazole was made available over the counter in 
February 2016. PPIs, proton pump inhibitors
marking the end of the programme with the release of 
the second Choosing Wisely PPI recommendation. We 
tested whether these initiatives resulted in a change in 
any of the three aforementioned rates following their 
implementation, including both a temporary shift (a 
sudden change only observed within the month of 
the intervention) and a level shift (a sudden, sustained 
change for the remainder of the study period).
sensitivity analysis
From June 2015, standard and low strength PPIs 
became available over the counter in only 7- day pack 
sizes in Australia (table 1). Since our data did not 
capture over- the- counter medicines, we conducted a 
sensitivity analysis to explore whether any observed 
change in dispensings count or rate of discontinuation 
in the main analysis was related to people switching 
to over- the- counter PPIs. We restricted this analysis 
to concessional beneficiaries as they have less finan-
cial incentive than the general population to buy 
medicines over the counter, due to receiving an addi-
tional social security subsidy for prescribed medicines. 
Concessional beneficiaries comprise roughly 24% of 
Australia’s population39 40 and mainly include people 
aged above 65 years and/or people who receive 
benefits for disability or low income. We considered 
concessional beneficiaries as those for whom every 
dispensing during the study period attracted a conces-
sional benefit.30
We conducted all analyses in SAS V.9.4 (SAS insti-
tute, Cary, NC, USA) and R V.3.43 (The R foundation 
for statistical computing, Vienna, Austria).
dAtA Access ApprovAl
Data access was granted by the Australian Depart-
ment of Human Services External Request Evaluation 
Committee (Approval Numbers: MI9829, MI10933). 
Direct access to the data and analytical files to other 
individuals or authorities is not permitted without the 
express permission of the approving human research 
ethics committees and data custodians.
results
We observed 579 594 people who were dispensed at 
least one PPI medicine from July 2012 to June 2018, 
of which 55% were women and the median age was 
57 years (IQR: 42–69 years). Over the study period, 
we observed a total of 12 040 021 dispensings of PPIs, 
the majority (82%) of which were prescribed by GPs. 
Standard strength dispensings accounted for 78%, 
high strength 17% and low strength 5% of all dispens-
ings. Standard strength esomeprazole (20 mg) and 
standard strength pantoprazole (40 mg) were the most 
commonly dispensed PPIs each comprising approxi-
mately 25% of all PPI dispensing. In the year following 
the initiatives, 76% of switches to a lower strength PPI 
were from high strength esomeprazole (40 mg) to a 
standard strength PPI, while, respectively, 2.6% and 
14.6% were from standard strength esomeprazole and 
standard strength pantoprazole to a low strength PPI 
(online supplementary table S1).
Impact of initiatives on ppI dispensing
Following the initiatives, from May 2016 until the end 
of the study period, we observed a sustained reduc-
tion in monthly PPI dispensings of −1.7% (95% CI: 
−2.9% to −0.4%), and no significant changes in statin 
dispensing (figure 1A, table 2).
This level change was driven by fewer dispensings 
(−1.7%, 95% CI: −2.7% to −0.7%) of standard 
strength PPIs from May 2016. We observed no signifi-
cant changes in high or low strength PPI dispensings at 
either intervention point (figure 1B, table 2).
Impact of initiative on discontinuation of ppI use and 
switching to a lower strength ppI
We did not observe any significant temporary or level 
changes in the monthly rate of PPI (or statin) discontinu-
ation at either intervention point (figure 2A, table 2). In 
addition, we did not observe any significant changes in 
rate of monthly switching from higher to lower strength 
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Table 2 Change in the monthly PPI dispensing counts, rate of switching to a lower strength PPIs and rates of treatment discontinuation 
at each intervention point, estimated using ARIMA models adjusted for seasonality




Level shift‡ from April 
2015
Level shift from May 
2016
% (95% CI) % (95% CI)
Dispensing counts
  PPIs (2,1,0) (0,1,0)12 164 361 0.6 (−0.7 to 2.0) −1.7 (−2.9 to −0.4)
  High strength (1,1,0) (0,1,0)12 28 728 −0.2 (−3.1 to 2.7) 0.3 (−2.6 to 3.3)
  Standard strength (0,1,1) (0,1,0)12 128 156 1.2 (0.1 to 2.3) −1.7 (−2.7 to −0.7)
  Low strength (0,1,1) (0,1,0)12 7481 −0.1 (−2.6 to 2.5) −0.8 (−2.9 to 1.4)
  Statins (control) (0,1,1) (0,1,1)12 187 407 1.0 (−1.1 to 3.3) −1.6 (−3.7 to 0.5)
Switching to lower strength PPI
(0,1,1) (1,0,0)12   3.0 (−1.6 to 7.7) 0.2 (−3.8 to 4.4)
Treatment discontinuation
  PPIs (2,1,0 1,1,0)12   −0.1 (−0.4 to 0.2) −0.1 (−0.4 to 0.2)
  Statins (control) (1,0,0) (0,1,0)12   0 (−0.3 to 0.4) 0.3 (0 to 0.6)
*ARIMA (p,d,q) x (P,D,Q)12 model where 12 indicates seasonal differencing at 12- month lag.
†Mean monthly dispensings in the year leading up to NPS MedicineWise programme in April 2015.
‡A sudden, sustained change for the remainder of the study period.
ARIMA, autoregressive integrated moving average;PPI, proton pump inhibitor.
Figure 2 (A) Monthly unadjusted and seasonally adjusted (dashed 
line) rate (%) of PPI and statin discontinuation among those covered 
by treatment; (B) rate of switching to a lower strength PPI among those 
dispensed standard or high strength PPIs each month, from January 
2013 to May 2018. NPS MedicineWise’s PPI program start and end and 
Choosing Wisely Australia recommendations 1 and 2 marked at April 2015 
and May 2016. Standard strength PPI esomeprazole was made available 
over the counter in February 2016. PPI, proton pump inhibitor.
PPIs at either intervention point (figure 2B, table 2). 
We observed a similar distribution of the time between 
dispensings in the year before, during and after the initi-
atives, suggesting that stepping down of PPI treatment 
by less frequent intake did not become more common 
after the initiatives (online supplementary figure S1).
sensitivity analysis
Concessional beneficiaries accounted for 46.4% 
(n=2 69 019) of our sample. Similar to our main anal-
ysis, we observed a reduction of −1.8% (95% CI: 
−2.9 to −0.7) in PPI dispensings from May 2016 until 
the end of the study period. However, we observed a 
simultaneous level shift in statin dispensing of −2.2% 
(95% CI: −3.6 to −0.7) (figure 3A and online supple-
mentary table S2), suggesting there may be some 
confounding effects due to factors outside the initia-
tives under evaluation. We also observed no significant 
changes in rates of discontinuation of PPIs (or statins) 
at either intervention points (online supplementary 
table S2 and online supplementary figure S2).
dIscussIon
The results of this population- based study demonstrate 
that the educational initiatives, led by NPS Medicine-
Wise and Choosing Wisely, had a limited impact on 
PPI use on a national level. We observed only a small 
(1.7%) decline in PPI dispensings following the initi-
atives, corresponding to approximately 27 941 fewer 
than expected dispensings from May 2016 to June 
2018. Despite the promotion of stepping down or 
discontinuing PPI treatment in these initiatives, we did 
not observe any changes in the rates of switching to 
lower PPI strengths or discontinuation of treatment. 
In fact, higher strength PPIs remained the dominant 
choice for Australians throughout the study period; 
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Figure 3 (A) Monthly unadjusted and seasonally adjusted (dashed 
line) concessional beneficiaries’ dispensing counts of PPIs and statins (B) 
concessional beneficiaries’ dispensing counts of PPIs by strength: high, 
standard and low, from July 2012 to May 2018. NPS MedicineWise’s PPI 
programme start and end and Choosing Wisely Australia recommendations 
1 and 2 marked at April 2015 and May 2016. Standard strength PPI 
esomeprazole was made available over the counter in February 2016. PPI, 
proton pump inhibitors.
low strength PPIs accounted for only 6% of PPI 
dispensing in the period following the initiatives.
Together, the two national initiatives provided a 
multifaceted approach to promote appropriate PPI 
prescribing, encouraging review of people using PPIs 
long- term and recommending individuals to step- down 
treatment, to lower dose or discontinue, where appro-
priate. The deprescribing of medicines is a well- known 
challenge.41 Nevertheless, a multitude of community- 
based interventions have been successful in influencing 
medicine prescribing on a local scale, in particular the 
deprescribing of antibiotics42 and sedative- hypnotics 
such as benzodiazepine.43 44 In contrast, there is rela-
tively little evidence concerning nationwide initiatives 
implemented to reduce inappropriate prescribing.
Pratt et al45 examined previous nationwide NPS 
MedicineWise PPI initiatives and found they increased 
the use of low strength PPIs and reduced the overall 
rate of PPI use among veterans in Australia. Differ-
ences in both the scope of initiatives, study design 
and population subgroup evaluated may explain the 
discrepancies between our findings and the Pratt et al 
study. Previous NPS MedicineWise initiatives included 
active components such as free educational outreach 
visits to GPs, which have been demonstrated to be 
successful,46 and complementary initiatives regarding 
appropriate PPI use directly targeted veterans.47 Our 
study examined more recent NPS MedicineWise and 
Choosing Wisely initiatives on a wider representa-
tive population of Australia using additional proxy 
measures such as switching and discontinuation to 
assess change in prescribing behaviour.
We did not observe any significant change in the rates 
of people switching from higher to lower strength PPIs 
or discontinuing treatment following the initiatives. 
Findings of a large UK primary care database study high-
lighted potentially inappropriate use by demonstrating 
that only 40% of new users treated with PPIs for over 
12 months attempted to step down to a lower strength, 
with only 8.7% discontinuing PPI treatment.4 In the 
UK, the dissemination of nationwide clinical guidelines 
on PPIs in 2002 appeared to have little impact on GP 
prescribing behaviour.27 Additional investigation into 
the long- term use of PPIs in Australia is warranted to 
improve policy and education related to appropriate 
prescribing of these widespread medicines.
The passive nature of these interventions may have 
been insufficient or not well targeted to perturb the root 
causes of inappropriate PPI prescribing. While multi-
faceted educational interventions have been shown 
to be more effective than dissemination of guidelines 
alone in achieving evidence- based practice,48 49 addi-
tional barriers to change need to be addressed for the 
best chance of success.50 51 In Australia, restrictions 
are often placed around prescribing subsidised medi-
cines to ensure use is cost- effective.30 Until May 2019, 
the PBS PPI restrictions did not align with treatment 
guidelines,52 53 this may have undermined the efforts 
of the national initiatives under study. Additionally, 
esomeprazole is the most commonly prescribed PPI in 
Australia,54 but interestingly no low strength formula-
tion (ie, 10 mg tablets) of this PPI is publicly subsidised, 
with only 10 mg sachets available on the Australian 
market. We observed very few step- down attempts 
from standard strength esomeprazole in our data, indi-
cating that the absence of a low strength esomeprazole 
may have discouraged the step down of PPIs to the 
lowest effective dose and potentially diminished the 
impact of the initiatives on low strength PPI uptake.
Our findings should be interpreted in context of 
with the study limitations. As an interrupted time 
series analysis cannot separate the effect of concur-
rent events, we conducted a control series design to 
adjust for time- varying confounders in interrupted 
time series analyses.55 Additionally, to account for the 
concurrent introduction of PPIs as over- the- counter 
medicines, we conducted a sensitivity analysis on 
concessional beneficiaries, who did not have a finan-
cial incentive to switch to over- the- counter PPI use. 
Our findings from this analysis were twofold. First, 
we observed a similar decline of PPI dispensing among 
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concessional beneficiaries (1.8%) as among the total 
population (1.7%), indicating that this small decline 
was not affected by the recent availability of over- 
the- counter PPI medicines. Second, we observed a 
simultaneous shift in dispensing of statins, the control 
medicine among concessional beneficiaries, suggesting 
that the minimal decline in PPI dispensings may have 
been influenced by factors outside of the initiatives 
assessed.
The PBS 10% sample is a nationally representative 
sample of the adult Australian population and allows for 
the longitudinal capture of medicine use30; however, our 
results may underestimate true PPI use in the commu-
nity, as private prescription claims, and over- the- counter 
medicine dispensings are not captured in our data. 
Another limitation of our study was our use of proxies 
rather than direct measures of the prescribing behaviours 
targeted in the interventions. We did not have informa-
tion on exact dose prescribed and therefore used tablet 
strength as a proxy for dose. This may have underes-
timated the number of switches to lower doses as our 
proxy measure did not capture people who reduced 
dose by less frequent intake of the same tablet strength 
that is, from one tablet per day to every other day or 
two tablets to one per day. However, our supplemen-
tary analysis suggested that stepping down PPI treatment 
in this manner did not become more common after the 
initiatives. We were not privy to information regarding 
individuals’ clinical indications for PPI use or severity of 
symptoms underlying treatment, and we thus could not 
determine the appropriateness of the observed changes 
in PPI use. Lastly, we did not include measures to address 
the fidelity of the educational initiatives assessed in this 
study.
The results of this study reinforce that stakeholders 
should review, and realign if necessary, regulatory 
and administrative incentives to facilitate the uptake 
of evidence- based practice. To this end, the Austra-
lian government have increased the restrictions on 
the prescribing of subsidised PPI formulations, effec-
tive from 1 May 2019, that is, after the end of our 
study period. These new restrictions53 are intended to 
further promote the use of lower strength PPIs and to 
contain long- term treatment of higher strength PPIs 
to clinically appropriate cases.56 The effectiveness of 
these regulatory efforts remains to be assessed.
conclusIons
In this study, we have demonstrated that the national 
educational initiatives targeting prescribers and 
patients have had a limited impact on improving 
quality use of PPIs. Higher strength PPI dispensing 
continues to comprise most PPI use in Australia. It 
appears that educational initiatives working alone are 
unlikely to make the inroads required to curb overuse 
of PPIs; policy levers such as imposing tighter restric-
tions on subsidised use of PPIs in concert with educa-
tion may be more effective. Furthermore, we believe 
that increased availability of low strength prepara-
tions, such as 10 mg esomeprazole tablets, could facil-
itate more appropriate management of PPI treatment.
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